Demographics and concomitant disorders in heart failure

Lancet

Volumn 362, Issue 9378, 2003, Pages 147-158

  Krum, Henry ^a,c   Gilbert, Richard E ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ERYTHROPOIETIN; HORMONE; IRBESARTAN; IRON; LOSARTAN; METFORMIN; NEBIVOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; SIMVASTATIN; STATIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

ANEMIA; ANTIARRHYTHMIC ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEYNE STOKES BREATHING; COGNITIVE DEFECT; COMORBIDITY; CORONARY ARTERY DISEASE; DEATH; DEFIBRILLATOR; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG TOLERABILITY; ENDOTHELIUM CELL; GENDER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFORMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SLEEP APNEA SYNDROME; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; WATER RETENTION;

EID: 0037629251     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13869-X     Document Type: Review

References (165)

1. Haldeman G.A., Croft J.B., Giles W.H., Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 137:1999;352-360.
2. Hoes A.W., Mosterd A., Grobbee D.E. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J. 19:1998;L2-L9.
3. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 22:1993;6A-13A.
4. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667.
5. Young J.B., Granger C.B., Yusuf S., et al. Patient characteristics in CHARM (Candesartan in heart failure-assessment of reduction in mortality and morbidity). J Card Failure. 7:(suppl):2001;55.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet. 353:1999;9-13.
7. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
8. Moller M., Torp-Pedersen C.T., Kober L. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. Congest Heart Fail. 7:2001;146-150.
9. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
10. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587.
11. Levine T.B., Bernink P.J., Caspi A., et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Circulation. 101:2000;758-764.
12. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT HF). Lancet. 353:1999;2001-2007.
13. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 19:1998;481-489.
14. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: prospective randomised amlodipine survival evaluation study. N Engl J Med. 335:1996;1107-1114.
15. Hampton J.R., van Veldhuisen D.J., Kleber F.X., et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: second prospective randomised study of ibopamine on mortality and efficacy. Lancet. 349:1997;971-977.
16. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study. N Engl J Med. 341:1999;709-717.
17. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
18. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
19. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
20. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675.
21. Brophy J. Epidemiology of congestive heart failure: Canadian data from 1970 to 1989. Can J Cardiol. 8:1992;495-498.
22. Chae C., Pfeffer M., Glynn R., Mitchell G., Taylor J., Hennekens C. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 281:1999;634-639.
23. Chen Y., Vaccarino V., Williams C., Butler J., Berkman L., Krumholz H. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 106:1999;605-612.
24. Remes J., Reunanen A., Aromaa A., Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 13:1992;588-593.
25. Ceia F., Fonseca C., Mota T., et al. Prevalence of chronic heart failure in Portugal: a community-based study (EPICA). Eur Heart J. 21:(suppl):2000;291.
26. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 285:1971;1441-1446.
27. Ho K., Anderson K., Kannel W., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:1993;107-115.
28. Ho K., Pinsky J., Kannel W., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 22:(suppl):1993;6A-13A.
29. Gillum R. Epidemiology of heart failure in the United States. Am Heart J. 126:1993;1042-1047.
30. McMurray J., McDonagh T., Morrison C., Dargie H. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J. 14:1993;1158-1162.
31. Mittelmark M., Psaty B., Rautaharju P., et al. Prevalence of cardiovascular diseases among older adults: the Cardiovascular Health Study. Am J Epidemiol. 137:1993;311-317.
32. Mosterd A., Reitsma J., Grobbee D. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart. 87:2002;75-76.
33. Anon. Changes in mortality from heart failure - United States, 1980-1995. MMWR Morb Mortal Wkly Rep 1998; 47: 633-37.
34. Murdoch D., Love M., Robb S., et al. Importance of heart failure as a cause of death: changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. Eur Heart J. 19:1998;1829-1835.
35. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 161:2001;996-1002.
36. Cowie M., Mosterd A., Wood D., et al. The epidemiology of heart failure. Eur Heart J. 18:1997;208-225.
37. Rodeheffer R., Jacobsen S., Gersh B., et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 68:1993;1143-1150.
38. Mosterd A., Hoes A., de Bruyne M., et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J. 20:1999;447-455.
39. Mosterd A., Cost B., Hoes A., et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J. 22:2001;1318-1327.
40. Senni M., Tribouilloy C., Rodeheffer R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 98:1998;2282-2289.
41. Senni M., Tribouilloy C., Rodeheffer R., et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 159:1999;29-34.
42. Agarwal A., Venugopalan P., de Bono D. Prevalence and aetiology of heart failure in an Arab population. Eur J Heart Fail. 3:2001;301-305.
43. Brown A., Cleland J. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 19:1998;1063-1069.
44. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med. 156:1996;1669-1673.
45. Croft J., Giles W., Pollard R., Casper M., Anda R., Livengood J. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc. 45:1997;270-275.
46. Ghali J., Giles T., Gonzales M., et al. Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure. J La State Med Soc. 149:1997;474-484.
47. Lowe J., Candlish P., Henry D., Wlodarcyk J., Heller R., Fletcher P. Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Med J Aust. 168:1998;115-118.
48. MacIntyre K., Capewell S., Stewart S., et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 102:2000;1126-1131.
49. McCullough P., Philbin E., Spertus J., Kaatz S., Sandberg K., Weaver W. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 39:2002;60-66.
50. Rodriguez-Artalejo F., Guallar-Castillon P., Banegas Banegas J., del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J. 18:1997;1771-1779.
51. Survey of heart failure in Italian hospital cardiology units: results of the SEOSI study. Eur Heart J. 18:1997;1457-1464.
52. Krum H., Tonkin A., Currie R., Djundjek R., Johnston C. Chronic heart failure in Australian general practice: the Cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust. 174:2001;439-444.
53. Clarke K., Gray D., Hampton J. How common is heart failure? Evidence from PACT (prescribing analysis and cost) data in Nottingham. J Public Health Med. 17:1995;459-464.
54. Mair F., Crowley T., Bundred P. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract. 46:1996;77-79.
55. Parameshwar J., Shackell M., Richardson A., Poole-Wilson P., Sutton G. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract. 42:1992;287-289.
56. Saunders E. Tailoring treatment to minority patients. Am J Med. 88:1990;S21-S23.
57. Sica D.A., Douglas J.G. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich). 3:2001;244-251.
58. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351-37.
59. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
60. Carson P., Ziesche S., Johnson G., Cohn J.N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 5:1999;178-187.
61. Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. J Med. 347:2002;1403-1411.
62. Shibata M., Flather M., Bohm M., et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Int J Cardiol. 86:2002;77.
63. Cleland J.G., Tendera M., Adamus J., et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail. 1:1999;211-217.
64. Topol E.J., Traill T.A., Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 312:1985;277-283.
65. Bonow R.O., Udelson J.E. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med. 117:1992;502-510.
66. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562.
67. Kostis J.B. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 8:1995;909-914.
68. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 278:1997;212-216.
69. Trial of treatment in older adults: principal results. BMJ. 304:1992;405-412.
70. Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
71. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (Syst-Eur). Lancet. 350:1997;757-764.
72. Swedberg K., Pfeffer M., Granger C., et al. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) - rationale and design. J Card Fail. 5:1999;276-282.
73. Sutton G.C. Epidemiologic aspects of heart failure. Am Heart J. 120:1990;1538-1540.
74. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 97:1998;282-289.
75. Vasan R.S., Benjamin E.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 26:1995;1565-1574.
76. Braunwald E., Rutherford J.D. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium" J Am Coll Cardiol. 8:1986;1467-1470.
77. Rahimtoola S.H. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol. 75:1995;E16-E22.
78. Elefteriades J.A., Tolis G. Jr, Levi E., Mills L.K., Zaret B.L. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 22:1993;1411-1417.
79. Ragosta M., Beller G.A., Watson D.D., Kaul S., Gimple L.W. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation. 87:1993;1630-1641.
80. Coletta A., Thackray S., Nikitin N., Cleland J.G. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002. Eur J Heart Fail. 4:2002;381-388.
81. Eitzman D., al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 20:1992;559-565.
82. Di Carli M.F., Asgarzadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 92:1995;3436-3444.
83. Harrison D.G. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 89:1994;87-102.
84. Lüscher T.F., Boulanger C.M., Dohi Y., Yang Z.H. Endothelium-derived contracting factors. Hypertension. 19:1992;117-130.
85. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the Trial on Reversing Endothelial Dysfunction Study. Circulation. 94:1996;258-265.
86. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study. N Engl J Med. 342:2000;145-153.
87. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
88. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 357:2001;1385-1390.
89. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 333:1995;77-82.
90. Woodley S.L., Gilbert E.M., Anderson J.L., et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
91. Stone P.H., Muller J.E., Hartwell T., et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis: the MILIS Study. J Am Coll Cardiol. 14:1989;49-57.
92. Gustafsson I., Hildebrandt P., Seibaek M., et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen: the TRACE Study. Eur Heart J. 21:2000;1937-1943.
93. Gustafsson I., Hildebrandt P. Early failure of the diabetic heart. Diabetes Care. 24:2001;3-4.
94. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 34:1974;29-34.
95. Chen Y.T., Vaccarino V., Williams C.S., Butler J., Berkman L.F., Krumholz H.M. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 106:1999;605-612.
96. Chae C.U., Pfeffer M.A., Glynn R.J., Mitchell G.F., Taylor J.O., Hennekens C.H. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 281:1999;634-639.
97. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 317:1998;703-713.
98. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
99. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 100:1999;1134-1146.
100. Tarnow L., Rossing P., Gall M.A., Nielsen F.S., Parving H.H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care. 17:1994;1247-1251.
101. Poirier P., Bogaty P., Garneau C., Marois L., Dumesnil J.G. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of manoeuvres in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 24:2001;5-10.
102. Bell D.S. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 18:1995;708-714.
103. Standl E., Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia. 43:2000;1455-1469.
104. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321:2000;405-412.
105. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 103:2001;2668-2673.
106. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 321:2000;412-419.
107. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010.
108. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
109. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
110. Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J. 20:1999;789-795.
111. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., Gersh B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 38:2001;421-428.
112. Gustafsson I., Torp-Pedersen C., Kober L., Gustafsson F., Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction (Trace Study). J Am Coll Cardiol. 34:1999;83-89.
113. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Effect of carvedilol on left ventricular dysfunction and mortality in diabetic versus non-diabetic patients with ischaemic or non-ischaemic dilated cardiomyopathy. Circulation. 94:1996;I-664.
114. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560.
115. Stevenson W.G., Sweeney M.O. Pharmacologic and nonpharmacologic treatment of ventricular arrhythmias in heart failure. Curr Opin Cardiol. 12:1997;242-250.
116. Stevenson W.G., Middlekauff H.R., Saxon L.A. Ventricular arrhythmias in heart failure. Zipes D.P., Jaife J. Cardiac electrophysiology: from cell to bedside. 1995;848-863 WB Saunders, Philadelphia.
117. Huikuri H.V., Castellanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med. 345:2001;1473-1482.
118. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial. N Engl J Med. 335:1996;1933-1940.
119. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unsustained Tachycardia Trial. N Engl J Med. 341:1999;1882-1890.
120. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
121. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883.
122. Lechat P., Hulot J.S., Escolano S., Mallet A., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 103:2001;1428-1433.
123. Joglar J.A., Acusta A.P., Shusterman N.H., et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 142:2001;498-501.
124. Krum H., Ninio D., MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart. 84:2000;615-619.
125. Salpeter S.S., Ormiston T., Salpeter E., Poole P., Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database Syst Rev. 2:2002;CD003566.
126. Andreas S. Central sleep apnea and chronic heart failure. Sleep. 23:2000;S220-S223.
127. Floras J.S., Bradley T.D. Sleep apnoea: a therapeutic target in congestive heart failure. Eur Heart J. 19:1998;820-821.
128. Tkacova R., Dajani H.R., Rankin F., Fitzgerald F.S., Floras J.S., Douglas Bradley D.T. Continuous positive airway pressure improves nocturnal baroreflex sensitivity of patients with heart failure and obstructive sleep apnea. J Hypertens. 18:2000;1257-1262.
129. Kaneko Y., Flora J.S., Usui K., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 348:2003;1233-1241.
130. Scall R.R., Petrucci R.J., Brozena S.C., Cavarocchi N.C., Jessup M. Cognitive function in patients with symptomatic dilated cardiomyopathy before and after cardiac transplantation. J Am Coll Cardiol. 14:1989;1666-1672.
131. Cacciatore F., Abete P., Ferrara N., et al. Congestive heart failure and cognitive impairment in the elderly. Arch Gerontol Geriatr. 20:1995;63-68.
132. Sever P. The SCOPE Trial. J Renin Angiotensin Aldosterone Syst. 3:2002;61-62.
133. Krum H., McMurray J.J.V. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 39:2002;1567-1573.
134. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
135. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
136. Mortensen S.A., Leth A., Agner E., Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 18:(suppl):1997;S137-S144.
137. McMurray J., Chopra M., Abdullah I., Smith W.E., Dargie H.J. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 14:1993;1493-1498.
138. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet. 356:2000;930-933.
139. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:2000;3060-3067.
140. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 353:1999;1838-1842.
141. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 3:1997;249-254.
142. Segal R., Pitt B., Poole Wilson P., Sharma D., Bradstreet D.C., Ikeda L.S. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail. 2:(suppl):2000;96.
143. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Meierhofer C., Djanani A., Wiedermann C.J. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis. 158:2001;23-33.
144. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 108:2001;391-397.
145. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
146. Rosnenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983-984.
147. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 104:2001;982-985.
148. Haber H.L., Leavy J.A., Kessler P.D., Kukin M.L., Gottlieb S.S., Packer M. The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med. 324:1991;353-358.
149. Rich M.W., Shah A.S., Vinson J.M., Freedland K.E., Kuru T., Sperry J.C. Iatrogenic congestive heart failure in older adults: clinical course and prognosis. J Am Geriatr Soc. 44:1996;638-643.
150. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 35:2000;1737-1744.
151. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 37:2001;1775-1780.
152. Ruilope L.M., van Veldhuisen D.J., Ritz E., Luscher T.F. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 38:2001;1782-1787.
153. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 102:2000;203-210.
154. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 35:2000;681-689.
155. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1997;1857-1863.
156. Feenstra J., Grobbee D.E., Mosterd A., Stricker B.H. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf. 17:1997;166-180.
157. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 160:2000;777-784.
158. Harris C.J., Brater D.C. Renal effects of cyclooxygenase-2 selective inhibitors. Curr Opin Nephrol Hypertens. 10:2001;603-610.
159. Katz S.D. The role of endothelin-derived vasoactive substances in the pathology of exercise intolerance in patients with congestive heart failure. Prog Cardiovasc Dis. 38:1995;23-50.
160. Cleland J.G.F. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 12:1997;276-287.
161. Teo K.K., Yusuf S., Pfeffer M., et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 360:2002;1037-1043.
162. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 96:1999;272-277.
163. Pisetsky D.S., St Clair E.W. Progress in the treatment of rheumatoid arthritis. JAMA. 286:2001;2787-2790.
164. Shan K., Kurrelmeyer K., Seta Y., et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol. 12:1997;218-223.
165. Louis A., Cleland J.G., Crabbe S., et al. Clinical Trials Update: highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 3:2001;381-387.